Our Portfolio company, Iktos announced a collaboration agreement in AI with Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer for kinase project. As per the agreement, NMS will leverage Iktos’s expertise in drug design services, with the ultimate goal of identifying at least one promising candidate molecule. Iktos’s innovative generative modeling technology platform, Makya™, will be employed to apply a ligand- and structure-based approach in designing novel molecules that align with NMS’s candidate drug target profile (CDTP).
We are excited and proud to collaborate with Nerviano Medical Sciences S.r.l, a leading company focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy. In the framework of our collaboration, the NMS team will use Makya, Iktos proprietary Gen AI software in their discovery of a novel candidate drug. Indeed, at Iktos, we are committed to developing innovative technologies that enhance the chance of success of small molecule discovery. Our mission is to expedite drug discovery through the application of AI, which we achieve by integrating our robust algorithmic technology, leveraging our expertise from numerous successful collaborations.
said Dr. Quentin Perron, Co-founder and CSO of Iktos.
Click here to access their full press release